Eli Lilly and Co. is providing more than $4 million in additional funding to the Infectious Disease Research Institute (IDRI) to continue its early phase drug discovery efforts to identify better therapies for tuberculosis, including multidrug-resistant strains known as MDR-TB. Lilly will also provide more than $1 million for volunteer time from Lilly scientists and access to the company’s drug discovery expertise, chemical libraries, and research tools. To date, Lilly has provided more than $2...